CEPI Launches CEPI 3.0 Pandemic Plan
Analysis based on 7 articles · First reported Feb 13, 2026 · Last updated Feb 20, 2026
The launch of Coalition for Epidemic Preparedness Innovations (CEPI)'s CEPI 3.0 plan is expected to positively impact the biotechnology and pharmaceutical industries by driving investment in vaccine research and manufacturing. This initiative aims to mitigate the economic and human costs of future pandemics, potentially stabilizing markets during health crises.
The Coalition for Epidemic Preparedness Innovations (CEPI) has unveiled its new five-year plan, CEPI 3.0, aimed at bolstering global defenses against dangerous viruses. The plan, launched on February 13, seeks US$2.5 billion in investment from governments, donors, and partners to enhance disease preparedness. Richard Hatchett, CEO of CEPI, highlighted the world's unpreparedness during COVID-19 and the ongoing threat from diseases like Ebola, Nipah, and Marburg. A core objective of CEPI 3.0 is the '100 Days Mission' to develop vaccines within 100 days of a new virus discovery, with a goal to secure 1 to 2 billion vaccine doses through regional manufacturing. The African Union===Africa Centres for Disease Control and Prevention (Africa CDC), through its Director-General Dr. Jean Kaseya, expressed its commitment to partnering with CEPI to strengthen surveillance and vaccine production capacity in Africa. CEPI has already secured US$1.1 billion and is collaborating with partners including the World Health Organization (WHO) to fully implement the plan, emphasizing that early investment will save lives and protect economies.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard